Luqa Pharmaceuticals, a China specialty care company focused on dermatology and other areas, completed a US$15 million Series A financing led by Morningside Ventures. The funds will be used to expand operations and commercialize Luqa's product range, which includes nine derma-aesthetic products launched since 2013. Luqa aims to provide innovative physician-driven solutions for Chinese patients and build a modern healthcare model adapted to China's needs through education. The financing will support substantially growing the business, according to Luqa's CEO.

1. Luqa Pharmaceuticals Completes US$15M Series A Financing
HONG KONG, June 9, 2015 /PRNewswire/ --
Luqa Pharmaceuticals, a China specialty care company that markets innovative solutions in dermatology and other specialty areas, announces
the completion of a US$15 million round of fund raising. The new financing was led by Morningside Ventures. Proceeds will be used to expand,
develop and fund on-going operations and commercialization of Luqa's product range.
Luqa has been able to record strong growth since the launch of its first product in 2013. Luqa has now launched an additional eight products, with
three more launches expected in 2015. Luqa has rapidly become a reference company in China's derma-aesthetic space offering medical,
corrective and aesthetic product lines, which are used mainly by physicians to enhance patients' appearance.
Luqa's solutions provide patients with best-in-class innovation whilst providing physicians and healthcare communities with continuous education
and training initiatives to ensure they are kept well informed about patient conditions and the needs of the patients with these conditions.
According to Luqa's CEO Robert Braithwaite, "The financing provides capital necessary to substantially grow, providing unique physician driven
solutions for Chinese patients. We continue to strive to build a modern healthcare model, well adapted to today's China needs, based on
strengthening the relationship between patients and providers through education and information."
"The proven track record of Luqa's team, together with its portfolio and distribution partnerships, create a very compelling future," said Michael
Xue from Morningside Ventures. "We are pleased to participate in the exciting model Luqa is developing, and look forward to working in assisting
the company in pursuit of its vision to be a standout innovator in the derma-aesthetics market and other specialty areas."
About Luqa
Luqa Pharmaceuticals is a China-focused company. We acquire, develop and commercialize innovative healthcare products that bring added
value to prescribers and other healthcare providers while enhancing quality of life for patients. Since its inception in 2010, Luqa has become a
fast-growing, revenue generating company. Please visit us athttp://www.luqapharma.com
About Morningside
Morningside is a diversified investment group founded in 1986 by the Chan family of Hong Kong. It is engaged primarily in private equity and
venture capital investments. The group has investments in North America, Europe, across Asia-Pacific, and since 1992, in Mainland China.
Morningside is an active investor in early-stage life science companies formed around new technologies that represent a high degree of novelty
over existing technologies. More information is available athttp://www.morningside.com
Contact
Robert Braithwaite - CEO - +8615601882962
Hugo Peris - Director - +34630171765
SOURCE Luqa Pharmaceuticals